My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

40.27 -0.55 (-1.36%)
Streaming Delayed Price Updated: 12:28 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Recent Report Shows That Rep. Robert Aderholt Sold Up to $15K Worth of GSK Stock
 
Via Benzinga
Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed
Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial... 
Via Benzinga
Topics Government
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates. 
Via Benzinga
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster'
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public... 
Via Benzinga
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
Via Stocktwits
What's Driving the Market Sentiment Around GSK?
 
Via Benzinga
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety. 
Via Benzinga
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens
Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez. 
Via Benzinga
GSK Secures UK Approval For First New Oral Antibiotic In 30 Years To Treat Resistant Urinary Tract Infections
Via Stocktwits
Price Over Earnings Overview: GSK
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public... 
Via Benzinga
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
What Does the Market Think About GSK?
 
Via Benzinga
How Is The Market Feeling About GSK?
 
Via Benzinga
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study
Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025. 
Via Benzinga
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets. 
Via Benzinga
GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’
GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate. 
Via Stocktwits
Topics Artificial Intelligence World Trade
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.